METTL21C: A Drug Target / Disease Biomarker (G196541)

Target Name: METTL21C

NCBI ID: G196541

METTL21C

METTL21C: A Drug Target / Disease Biomarker

METTL21C is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the METTL family of proteins, which are known for their role in regulating mitochondrial dynamics and energy metabolism. METTL21C has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

The METTL family of proteins was first identified in the 1990s based on the analysis of genetic variation in the gene encoding the protein. These proteins are characterized by a conserved catalytic core and a unique N-terminal region that includes a leucine-rich repeat (LRR) and a conserved motif known as the METTL domain. METTL21C is a member of the METTL family and is located at position 21 on the protein sequence.

METTL21C is a 21 kDa protein that consists of 21 amino acid residues. It has a characteristic N-terminal region that includes a LRR and a conserved motif known as the METTL domain. The METTL domain is a conserved region that is present in multiple organisms and is involved in the regulation of various cellular processes, including mitochondrial dynamics and energy metabolism.

The METTL21C protein is expressed in various tissues of the body, including the brain, heart, and kidneys. It is highly expressed in the brain and is also expressed in the heart and kidneys. METTL21C is a good candidate for a drug target because of its unique structure and its involvement in important cellular processes.

One of the potential benefits of targeting METTL21C is its potential to treat various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. METTL21C has been shown to be involved in the regulation of mitochondrial dynamics and energy metabolism, which could be useful for targeting diseases that are characterized by disruptions in these processes.

For example, METTL21C has been shown to be involved in the regulation of mitochondrial dynamics in neurodegenerative diseases. METTL21C has been shown to play a role in the export of mitochondrial proteins to the cytoplasm, which is thought to be important for the regulation of mitochondrial dynamics. METTL21C mutations have been shown to cause neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, targeting METTL21C with drugs that modulate its mitochondrial dynamics could be a promising approach to treating neurodegenerative diseases.

Another potential application of METTL21C as a drug target is its involvement in cardiovascular disease. METTL21C has been shown to be involved in the regulation of mitochondrial dynamics and energy metabolism, which could be useful for targeting diseases that are characterized by disruptions in these processes. For example, METTL21C mutations have been shown to cause cardiovascular disease, including heart failure and hypertension. Therefore, targeting METTL21C with drugs that modulate its mitochondrial dynamics could be a promising approach to treating cardiovascular disease.

In conclusion, METTL21C is a protein that is expressed in various tissues of the body and has been identified as a potential drug target or biomarker for various diseases. Its unique structure and its involvement in important cellular processes make it an attractive target for drug development. Further research is needed to fully understand the role of METTL21C in disease and to develop effective treatments.

Protein Name: Methyltransferase 21C, AARS1 Lysine

Functions: Protein-lysine methyltransferase

The "METTL21C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL21C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets